Financial results: Rua Bioscience; Elixinol Wellness; Argent Biopharma; Wellnex Life; InhaleRx; Bioxyne by Martin Lane and Steve Jones September 2, 2024September 3, 2024 An asset write down of NZ$8.5 million (A$7.86m) saw New Zealand-based Rua Bioscience post a loss […]
Wellnex launches medicinal cannabis brand, appoints two new medical advisors by Martin Lane August 16, 2024August 22, 2024
Wellnex shelves low dose S3 move amid ‘remote’ chance of registration by Steve Jones June 11, 2024June 11, 2024
Wellnex to launch range of cannabis medicine as more products enter market by Steve Jones June 5, 2024June 6, 2024
Financial results: Bioxyne; Rua Bioscience; Bod Science; Avecho; Wellnex Life; MGC Pharma; Cannasouth by Steve Jones March 7, 2024March 7, 2024
Quarterly results: Elixinol; Emyria; Ecofibre; LGP; Bioxyne/BLS; Epsilon; Melodiol; MGC Pharma; AusCann; Neurotech; Wellnex Life; InhaleRx; Cannasouth by Steve Jones and Martin Lane November 1, 2023November 6, 2023
Financial results: Avecho; Wellnex; Zelira; Emyria; Botanix; MGC Pharma; AusCann; Epsilon; Melodiol; Bioxyne by Martin Lane and Steve Jones September 4, 2023April 30, 2024
Wellnex Life snaps up topical pain relief brand to complement medicinal cannabis strategy by Martin Lane May 29, 2023April 30, 2024
Company news: Wellnex Life; Creso Pharma; MGC Pharma; Zelira Therapeutics by Martin Lane March 16, 2023April 30, 2024
Company news: Releaf Group; Bod; Wellnex Life; MGC Pharma; MediCann Health by Martin Lane October 27, 2022April 29, 2024
